- Home
- BOOT vs AXSM Comparison
BOOT vs AXSM Comparison
Compare BOOT & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOOT
- AXSM
- Stock Information
- Founded
- BOOT 1978
- AXSM 2012
- Country
- BOOT United States
- AXSM United States
- Employees
- BOOT N/A
- AXSM N/A
- Industry
- BOOT Clothing/Shoe/Accessory Stores
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- BOOT Consumer Discretionary
- AXSM Health Care
- Exchange
- BOOT Nasdaq
- AXSM Nasdaq
- Market Cap
- BOOT 4.8B
- AXSM 4.2B
- IPO Year
- BOOT 2014
- AXSM 2015
- Fundamental
- Price
- BOOT $149.97
- AXSM $84.60
- Analyst Decision
- BOOT Strong Buy
- AXSM Strong Buy
- Analyst Count
- BOOT 11
- AXSM 14
- Target Price
- BOOT $170.64
- AXSM $125.54
- AVG Volume (30 Days)
- BOOT 626.8K
- AXSM 893.5K
- Earning Date
- BOOT 01-29-2025
- AXSM 02-18-2025
- Dividend Yield
- BOOT N/A
- AXSM N/A
- EPS Growth
- BOOT N/A
- AXSM N/A
- EPS
- BOOT 4.98
- AXSM N/A
- Revenue
- BOOT $1,758,043,000.00
- AXSM $338,457,000.00
- Revenue This Year
- BOOT $15.90
- AXSM $44.77
- Revenue Next Year
- BOOT $14.13
- AXSM $67.70
- P/E Ratio
- BOOT $30.30
- AXSM N/A
- Revenue Growth
- BOOT 3.51
- AXSM 51.47
- 52 Week Low
- BOOT $69.35
- AXSM $64.11
- 52 Week High
- BOOT $169.83
- AXSM $105.00
- Technical
- Relative Strength Index (RSI)
- BOOT 47.84
- AXSM 43.66
- Support Level
- BOOT $153.89
- AXSM $79.19
- Resistance Level
- BOOT $168.74
- AXSM $87.53
- Average True Range (ATR)
- BOOT 6.39
- AXSM 4.37
- MACD
- BOOT -0.37
- AXSM -0.02
- Stochastic Oscillator
- BOOT 24.68
- AXSM 61.27
About BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.